Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.
Endocrinol Diabetes MetabSep 1, 2026
Chia Siang Kow, Kaeshaelya Thiruchelvam, Dinesh Sangarran Ramachandram et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis examined weight regain trajectories following the discontinuation of semaglutide or tirzepatide in 1776 participants across six studies. The analysis estimated an initial weight loss of 15.35 kg, with a regain rate of 1.04 kg/month. It projected that 50% of the initial weight loss would be regained by 7.50 months.
Key findings
- Estimated weight loss at cessation was 15.35 kg (95% CrI 11.18-19.60).
- Weight regain rate was 1.04 kg/month (95% CrI 0.80-1.29).
- 50% of initial weight loss was projected to be regained by 7.50 months (95% CrI 5.05-10.57).
- Return to baseline weight was estimated by 15.00 months (95% CrI 10.10-21.13).
Why it matters
Understanding weight regain patterns after discontinuation of these medications is crucial for clinicians to develop effective long-term management strategies for patients, ensuring sustained weight loss and improved health outcomes.